#### Form 45-106F6

### British Columbia Report of Exempt Distribution

This is the form required under section 6.1 of National Instrument 45-106 for a report of exempt distribution in British Columbia.

#### **Issuer/underwriter information**

### Item 1: Issuer/underwriter name and contact information

A. State the following:

- the full name of the issuer of the security distributed. Include the former name of the issuer if its name has changed since this report was last filed;
- the issuer's website address; and
- the address, telephone number and email address of the issuer's head office.
- B. If an underwriter is completing this report, state the following:
  - the full name of the underwriter:
  - the underwriter's website address; and
  - the address, telephone number and email address of the underwriter's head office.

Antibe Therapeutics Inc. (the "Corporation")
15 Prince Arthur Avenue
Toronto, Ontario
M5R 1B2
Phone No. 905-726-0995

Website: http://antibethera.com/

Email: michael.bumby@antibethera.com

#### **Item 2: Reporting issuer status**

A. State whether the issuer is or is not a reporting issuer and, if reporting, each of the jurisdictions in which it is reporting.

The Issuer is a reporting issuer in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario.

B. If the issuer is an investment fund managed by an investment fund manager registered in a jurisdiction of Canada, name the investment fund manager and state the jurisdiction(s) where it is registered.

# Not Applicable.

#### **Item 3: Issuer's industry**

Indicate the industry of the issuer by checking the appro	priate box below.
☐ Bio-tech	Mining
Financial Services	exploration/development
investment companies and funds	production
mortgage investment companies	Oil and gas
Forestry	Real estate
☐ Hi-tech	Utilities
☐ Industrial	Other (describe)
	<u>Pharmaceutical</u>

# Item 4: Insiders and promoters of non-reporting issuers

If the issuer is an investment fund managed by an investment fund manager registered in a jurisdiction of Canada, do not complete this table.

If the issuer is not a reporting issuer in any jurisdiction of Canada, complete the following table by providing information about each insider and promoter of the issuer. If the insider or promoter is not an individual, complete the table for directors and officers of the insider or promoter.

Information about insiders and promoters					
Full name, municipality and country of principal residence	All positions held (e.g., director, officer, promoter and/or holder of more than 10% of voting securities)	Number and type of securities of the issuer beneficially owned or, directly or indirectly controlled, on the distribution date, including any securities purchased under the distribution	Total price paid for all securities beneficially owned or, directly or indirectly controlled, on the distribution date, including any securities purchased under the distribution (Canadian \$)		
Not Applicable					

#### **Details of distribution**

# **Item 5: Distribution date**

State the distribution date. If this report is being filed for securities distributed on more than one distribution date, state all distribution dates.

### December 30, 2013.

### **Item 6: Number and type of securities**

For each security distributed:

- describe the type of security;
  - o units of securities of the Corporation ("Units"), each Unit comprised of one Common Share and one half of a Warrant where each full Warrant entitles the holder to purchase one Common Share of the Corporation ("Warrant Share") at a price of \$0.80 per Warrant Share for a term of thirty six (36) months following the date of issuance.
  - o non-transferable finder warrants (issued to the finders, as set out under Item 9 Commissions and finder's fees) (each, a "Finder Warrant"), each of which will entitle the holder to purchase a Common Share at a price of \$0.55 per share until December 30, 2015.
- state the total number of securities distributed. If the security is convertible or exchangeable, describe the type of underlying security, the terms of exercise or conversion and any expiry date; and
  - o 1,635,354 Units.
  - o 139,444 Finder Warrants
- if the issuer is an investment fund managed by an investment fund manager registered in a jurisdiction of Canada, state the exemption(s) relied on. If more than one exemption is relied on, state the amount raised using each exemption.

#### **Item 7: Geographical information about purchasers**

Complete the following table for each Canadian and foreign jurisdiction where purchasers of the securities reside. Do not include in this table information about securities issued as payment of commissions or finder's fees disclosed under item 9 of this report. The information provided in this table must reconcile with the information provided in item 8 and Schedules I and II.

Each Canadian and foreign jurisdiction where purchasers reside	Number of purchasers	Price per security (Canadian \$) <sup>1</sup>	Total dollar value raised from purchasers in the jurisdiction (Canadian \$)
Ontario	5	0.55	\$148,500
Alberta	3	0.55	\$77,000
Quebec	7	0.55	\$369,299.70
British Columbia	19	0.55	\$288,145
Foreign	1	0.55	\$16,500
Total number of Purchasers	35		
Total dollar value of distribution in all jurisdictions (Canadian \$)			\$899,444.70

Note 1:If securities are issued at different prices, list the highest and lowest price for which the securities were sold.

#### **Item 8: Information about purchasers**

**Instructions** 

A. If the issuer is an investment fund managed by an investment fund manager registered in a jurisdiction of Canada, do not complete this table.

B. Information about the purchasers of securities under the distribution is required to be disclosed in different tables in this report. Complete

- the following table for each purchaser that is not an individual, and
- the tables in Schedules I and II of this report for each purchaser who is an individual.

Do not include in the tables information about securities issued as payment of commissions or finder's fees disclosed under item 9 of this report.

C. An issuer or underwriter completing this table in connection with a distribution using the exemption in subparagraph 6.1(1)(j) [TSX Venture Exchange offering] of National Instrument 45-106 Prospectus and Registration Exemptions may choose to replace the information in the

first column with the total number of purchasers, whether individuals or not, by jurisdiction. If the issuer or underwriter chooses to do so, then the issuer or underwriter is not required to complete the second column or the tables in Schedules I and II.

Information about non-individual purchasers					
Full name and address of purchaser and name and telephone number of a contact person	Indicate if the purchaser is an insider (I) of the issuer or a registrant (R)	Number and type of securities purchased	Total purchase price (Canadian \$)	Exemption relied on	Date of distribution (yyyy-mm-dd)
Bloom Burton Healthcare Fund; 121 King St. W. Suite 1820 Toronto, ON M5H 3T9 Tel #: 416 494 9934	registrant (11)	90,000 Units	49,500	s. 2.3 of NI 45-106	Dec 30 2013
The K2 Principal Fund LP; 2 Bloor Street W., Suite 801 Toronto, ON M4W 3E2 Tel #: 416 365 2155 X0		90,909 Units	49,999.95	s. 2.3 of NI 45-106	Dec 30 2013
Ardent Strategies Corp; 888 Dunsmuir St. Suite 1100, Vancouver, BC V6C 3K4 Tel #: 604 304 4089		36,000 Units	19,800	s. 2.3 of NI 45-106	Dec 30 2013
RPC Strategies; 888 Dunsmuir St. Suite 1100, Vancouver, BC V6C 3K4 Tel #: 604 304 4091		75,000 Units	41,250	s. 2.3 of NI 45-106	Dec 30 2013
Skar Holdings Ltd; 3436 Theodosia Ave., Powell River, BC V8A 5T5 Tel #: 604 483 6330		25,000 Units	13,750	s. 2.3 of NI 45-106	Dec 30 2013
Dr. Alnoor Somji Inc. 1501 Eastern Avenue , North Vancouver, BC		20,000 Units	11,000	s. 2.3 of NI 45-106	Dec 30 2013

Information about non-individual purchasers					
Full name and address of purchaser and name and telephone number of a contact person	Indicate if the purchaser is an insider (I) of the issuer or a registrant (R)	Number and type of securities purchased	Total purchase price (Canadian \$)	Exemption relied on	Date of distribution (yyyy-mm-dd)
V7L 3G2 Tel #: 604 988 2555					

### Commissions and finder's fees

### Item 9: Commissions and finder's fees

### Instructions

A. Complete the following table by providing information for each person who has received or will receive compensation in connection with the distribution(s). Compensation includes commissions, discounts or other fees or payments of a similar nature. Do not include information about payments for services incidental to the distribution, such as clerical, printing, legal or accounting services.

B. If the securities being issued as compensation are or include convertible securities, such as warrants or options, add a footnote describing the terms of the convertible securities, including the term and exercise price. Do not include the exercise price of any convertible security in the total dollar value of the compensation unless the securities have been converted.

Full name	Indicate if the person being	C	Compensation paid or to be paid (cash and/or securities)			
and address	compensated		Securities			
being compensated is an insider (I) of the issuer or a registrant (R)	Cash (Canadian \$)	Number and type of securities issued	Price per security (Canadian \$)	Exemption relied on and date of distribution (yyyy-mm-dd)	Total dollar value of compensation (Canadian \$)	
Jordan Capital Markets Inc. 1075 W. Georgia Street Suite 1920 Vancouver, British Columbia V6E 3C9	R	\$27,439.50	49,890 Finders Warrants	Nil	s. 2.3 of NI 45-106	\$27,439.50

EMD Financial Inc. 398 DeMaisonne uve Ouest Montreal, Quebec H3A 1L2	R	\$9,350.00	17,000 Finders Warrants	Nil	s. 2.3 of NI 45-106	\$9,350.00
Raymond James Ltd. 925 West Georgia Street Suite 400 Vancouver, British Columbia V6C 3L2	R	\$37,754.97	68,645 Finders Warrants	Nil	s. 2.3 of NI 45-106	\$37,754.97
Fidelity Clearing Canada 483 Bay Street South Tower Suite 200 Toronto, Ontario M5G 2N7	R	\$2,150.00	3,909 Finders Warrants	Nil	s. 2.3 of NI 45-106	\$2,150.00

#### Certificate

On behalf of the [issuer/underwriter], I certify that the statements made in this report are true.

Date: January 15, 2014.

Antibe Therapeutics Inc.

Name of Issuer (please print)

Michael Bumby, Chief Financial Officer - 905-726-0995

Print name, title and telephone number of person signing

"Michael Bumby"

Signature

Instruction

The person certifying this report must complete the information in the square brackets by deleting the inapplicable word. For electronic filings, substitute a typewritten signature for a manual signature.

# **Item 10: Contact information**

State the name, title and telephone number of the person who may be contacted with respect to any questions regarding the contents of this report, if different than the person signing the certificate.

#### IT IS AN OFFENCE TO MAKE A MISREPRESENTATION IN THIS REPORT.

**Notice - Collection and use of personal information** 

The British Columbia Securities Commission collects and uses the personal information required to be included in this report for the administration and enforcement of the *Securities Act*. If you have any questions about the collection and use of this information, contact the British Columbia Securities Commission at the following address:

# **British Columbia Securities Commission**

P.O. Box 10142, Pacific Centre 701 West Georgia Street

Vancouver, British Columbia V7Y 1L2

Telephone: (604) 899-6500

Toll free across Canada: 1-800-373-6393

Facsimile: (604) 899-6581